First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Piccart-Gebhart, Martine J
  • Holmes, Andrew Peter
  • Baselga, Jose
  • De Azambuja, Evandro
  • Dueck, Amylou C
  • Viale, Giuseppe
  • Zujewski, Jo Anne
  • Goldhirsch, Aron
  • Santillana, Sergio
  • Pritchard, Kathleen
  • Wolff, Antonio C
  • Jackisch, Christian
  • Lang, Istvan
  • Untch, Michael
  • Smith, Ian E
  • Boyle, Frances
  • Xu, Binghe
  • Gomez, Henry Leonidas
  • Gelber, Richard D
  • Perez, Edith A

publication date

  • May 20, 2014